Alere Hit With Another Federal Subpoena, Casting More Doubt On Abbott Deal
Executive Summary
The company says the matters under investigation are immaterial, but the stock market disagrees, taking about a billion dollars from embattled diagnostics company in under a half-hour.
You may also be interested in...
Earnings Winners & Losers: QGEN, WMGI, ALR, SN, and LIVN
Diagnostics, orthopedics, and cardiovascular device companies are among those that wait until November to report their results for the quarter that ended at the end of September. Medtech Insight’s Earnings Winners & Losers highlights some of the companies that had news to celebrate, and a few that were disappointed with the quarter.
Abbott, Alere Agree To Mediation For Troubled Merger
Abbott announced plans to purchase Alere in January, but the merger has so far been delayed by, Alere alleges, Abbott's foot-dragging. Abbott, meanwhile, points to federal investigations that have delayed Alere’s financial filings.
Alere Sues To Compel Completion Of Abbott Merger
Abbott's confidence in the planned $5.8b deal has declined since the acquisition was announced in January following disclosures of investigations into Alere's business practices. Alere hopes the suit will prod Abbott to speed its efforts to secure regulatory approvals for the merger.